GlassScriptPhysician profile
Michael Burton Dillon
NPI 1346314069
$677.76
in general payments reported to CMS, 2019-2025
10 companies · $44.55 in 2025
The $44.55 reported for 2025 was less than what a typical Gynecologic Oncology provider received nationally (typical 2025 total: $305).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $55.94 · 2020: $234 · 2021: $146 · 2022: $61.69 · 2023: $38.35 · 2024: $97.08 · 2025: $44.55.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $180.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $179.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $265.18 | 2020-2024 | Lynparza |
| Glaxosmithkline, LLC. | $145.83 | 2021 | |
| Merck Sharp & Dohme LLC | $134.61 | 2019-2025 | Lynparza, Keytruda |
| Davol INC. | $29.29 | 2025 | Surgiphor |
| Pacira Pharmaceuticals Incorporated | $24.99 | 2019 | |
| Aroa Biosurgery Incorporated | $24.85 | 2022-2023 | |
| Tesaro, INC. | $17.33 | 2019 | |
| Ethicon US, LLC | $14.56 | 2024 | Surgiflo Hemostatic Matrix |
| Integra Lifesciences Corporation | $13.57 | 2022 | |
| Kerecis Limited | $7.55 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Graftguide, Kerecis Omega3 Surgiclose |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Dillon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.